On December 03, 2019, Exelixis, Inc. (NASDAQ:EXEL) shares lost -0.18% or -0.03 points to close at $16.67 with a heavy trading volume of 3.973 million shares. It opened the trading session at $16.55, the shares rose to $16.72 and dropped to $16.055, the range by which the price of stock traded the whole day. The company now has a market cap of $5.05 billion and currently has 302.75 million outstanding shares. Exelixis, Inc. (EXEL) stock has accumulated 4.12 percent of market value in 21 trading days.
EXEL stock’s trailing 3-year beta is 1.75, meaning there will be a greater rate of return, although posing a higher risk. The part of a firm’s profit given to each outstanding share of regular stock was $1.96 share in the trailing 52 weeks. The stock’s value fallen -15.25 percent year to date (YTD) compared to a decline of -17.92 percent in 52 week’s period. The firm’s shares are still trading -34.14 percent below its 1-year high of $25.31 and 10.99 percent up from 52-week low of $15.02. The average consensus ranking on the company is 2, on a ranging where 5 is equal to a consensus sell rating. In other words, the mean analyst recommendations are ranking this stock as a buy.
Exelixis, Inc. (EXEL) is most likely going to rise 46.13 percent in the coming 12 months, as per price target approximations compiled by finviz. Nevertheless, they have set the price target at a $35-month high price target. This represents a whopping 109.96 percent increase from the current trading of shares. The 52-week median price target given by the analysts is $23, which means a return possibility of 37.97 percent in comparison with the closing price of the stock of $16.67 on December 03. The lowest price set for the stock is $19 — just above 13.98 percent from EXEL share price now.
Past records have indicated that shares in Exelixis, Inc. declined on 20 different earnings reaction days and we have yet to see whether this trend will play out and remain in place when the company reports upcoming earnings. Investors will get the next hint of EXEL’s Q4 earnings on March 03. Analysts are predicting revenue to climb 2.8 percent to $235M in the financial fourth quarter, while EPS will soar by about -88.7 percent to $0.13 per share. In the last quarter, it earnings of $0.25 per share came better than the $0.23273, adjusted, expected by Thomson Reuters consensus estimate. Revenue for the quarter was $228.6M, topping the $188.44M analysts had expected. Earnings are seen to rise by 346.3 percent this year, 0 percent in the coming year and the trend continues by 46 percent every year in the next 5 years.
Let’s take a glimpse at some insider activity at Exelixis, Inc. (NASDAQ:EXEL) and observe the pattern. The earliest insider trade happened on 11/04/2019. Schwab Gisela parted with a total of 50 thousand shares of the firm at average share price of $15.99. The total amount for the sale was set at $799.5 thousand. On completing this exchange, the Pres, Prod Dev & Med Aff & CMO account balance was 339.21 thousand shares. The stock grew 4.44 percent from that insider sale. On 10/10/2019, Haley Patrick J., Sr. Vice President, Commercial, did a sale of 0.3 thousand shares at a price of $16.27 per share. This got rid of 4.93 thousand shares from the insider’s fortune and the stock experienced a 2.64 percent rally in price since the news became public. This exchange saw 123.4 thousand shares get out from the Sr. Vice President, Commercial account.
On 10/02/2019, President and CEO MORRISSEY MICHAEL recorded a sale transaction valued at $465.59 thousand. The sale at $17.66 a share has eliminated 26.36 thousand shares from the insider’s portfolio position. Meanwhile, shares price witnessed -5.44 percent decrease since the transaction reporting date. The company insider is left with 416.88 thousand shares remaining in the account. Schwab Gisela, who works as Pres, Prod Dev & Med Aff & CMO at the company, performed a sale of 30 thousand shares in a transaction worth $536.1 thousand. The disposal recorded on 10/01/2019 was priced at $17.87 per share. The stock price plunged -6.55 percent since the transaction. Schwab Gisela currently holds a stake of 339.21 thousand in EXEL stock which is worth $5.65 million after the insider selling.
The stock is lingering around the initial support level of $16.24. After this, the following support is at the zone of $15.82. Up until the time the EXEL stock hit levels beyond the current one, bulls should have no alarm. In terms of its momentum, the stock’s RSI hit 53.11 on the daily chart, and this may be a cause for concern. In case the price goes below $15.82 level on closing basis, there may be more profit booking with the stock growing weaker. Still, getting to the $16.91 level may cause a pull-back move approaching $17.15 mark.
Exelixis, Inc. has a 96.9% gross profit margin, with its operating margin around 42.2%. Alongside this, the company’s net profit margin currently stands at 64%.